AnaptysBio, Inc. (ANAB)

21,00 +2,13 (+11,29%) Al cierre: 04:00PM EDT

AnaptysBio, Inc.

10770 Wateridge Circle
Suite 210
San Diego, CA 92121-5801
United States
858 362 6295
https://www.anaptysbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 117

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Daniel R. Faga	President, CEO & Director	2,52M	N/A	1980
Mr. Eric J. Loumeau	Chief Legal Officer	722k	N/A	1963
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.	Chief Medical Officer	738,87k	N/A	1975
Mr. Dennis M. Mulroy	Chief Financial Officer	448,81k	N/A	1955
Ms. Beth Mueller	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Martin Dahl Ph.D.	Senior Vice President of Research	N/A	N/A	N/A
Mr. Benjamin Stone	Chief Business Officer	N/A	N/A	N/A
Mr. Douglas A. Rich M.B.A.	Senior Vice President of CMC	N/A	N/A	1969
Ms. Monique Da Silva	Senior Vice President of Corporate Affairs	N/A	N/A	N/A
Ms. Priya Raina	Senior Vice President of Clinical Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Gobierno corporativo

El ISS Governance QualityScore de AnaptysBio, Inc., a día 1 de abril de 2024, es 10. Las puntuaciones base son Auditoría: 9; Tablero: 9; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.